CN107484416A - 能够结合cd19和cd3的双特异性单价双抗体及其用途 - Google Patents

能够结合cd19和cd3的双特异性单价双抗体及其用途 Download PDF

Info

Publication number
CN107484416A
CN107484416A CN201580051198.9A CN201580051198A CN107484416A CN 107484416 A CN107484416 A CN 107484416A CN 201580051198 A CN201580051198 A CN 201580051198A CN 107484416 A CN107484416 A CN 107484416A
Authority
CN
China
Prior art keywords
domain
ser
val
dart
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580051198.9A
Other languages
English (en)
Chinese (zh)
Inventor
莱斯利·S·约翰逊
埃兹奥·泊韦尼
郭家颖
保罗·A·摩尔
刘丽勤
S·凯尼格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Macrogenics Inc
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of CN107484416A publication Critical patent/CN107484416A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Epoxy Compounds (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Furan Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
CN201580051198.9A 2014-09-26 2015-09-22 能够结合cd19和cd3的双特异性单价双抗体及其用途 Pending CN107484416A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462055695P 2014-09-26 2014-09-26
US62/055,695 2014-09-26
PCT/US2015/051314 WO2016048938A1 (en) 2014-09-26 2015-09-22 Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof

Publications (1)

Publication Number Publication Date
CN107484416A true CN107484416A (zh) 2017-12-15

Family

ID=55581876

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580051198.9A Pending CN107484416A (zh) 2014-09-26 2015-09-22 能够结合cd19和cd3的双特异性单价双抗体及其用途

Country Status (29)

Country Link
US (4) US10633443B2 (cg-RX-API-DMAC7.html)
EP (1) EP3197917B1 (cg-RX-API-DMAC7.html)
JP (1) JP6839075B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170063755A (cg-RX-API-DMAC7.html)
CN (1) CN107484416A (cg-RX-API-DMAC7.html)
AP (1) AP2017009823A0 (cg-RX-API-DMAC7.html)
AR (1) AR101997A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015321546B2 (cg-RX-API-DMAC7.html)
CA (1) CA2962603A1 (cg-RX-API-DMAC7.html)
CL (1) CL2017000711A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017002793A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170109A (cg-RX-API-DMAC7.html)
CU (1) CU20170041A7 (cg-RX-API-DMAC7.html)
DO (1) DOP2017000083A (cg-RX-API-DMAC7.html)
EA (1) EA201790719A1 (cg-RX-API-DMAC7.html)
ES (1) ES2935062T3 (cg-RX-API-DMAC7.html)
IL (1) IL251377B (cg-RX-API-DMAC7.html)
MA (1) MA40573A (cg-RX-API-DMAC7.html)
MD (1) MD20170040A2 (cg-RX-API-DMAC7.html)
MX (1) MX375669B (cg-RX-API-DMAC7.html)
NI (1) NI201700037A (cg-RX-API-DMAC7.html)
PE (1) PE20170894A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017500544A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201702310QA (cg-RX-API-DMAC7.html)
TN (1) TN2017000106A1 (cg-RX-API-DMAC7.html)
TW (1) TWI706960B (cg-RX-API-DMAC7.html)
UY (1) UY36316A (cg-RX-API-DMAC7.html)
WO (1) WO2016048938A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201701985B (cg-RX-API-DMAC7.html)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109402168A (zh) * 2018-10-30 2019-03-01 深圳新诺微环生物科技有限公司 微环dna表达连接her2阳性细胞与效应细胞的桥接分子及其应用
CN109957026A (zh) * 2017-12-22 2019-07-02 成都恩沐生物科技有限公司 共价多特异性抗体
WO2020088605A1 (zh) * 2018-11-01 2020-05-07 安源医药科技（上海）有限公司 针对cd19和cd3的同源二聚体型双特异性抗体及其制备方法和用途
CN112111012A (zh) * 2019-06-20 2020-12-22 成都恩沐生物科技有限公司 共价多特异性抗体
CN113488112A (zh) * 2021-06-10 2021-10-08 五邑大学 一种共价结合预测方法及装置

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
CN107484416A (zh) * 2014-09-26 2017-12-15 宏观基因有限公司 能够结合cd19和cd3的双特异性单价双抗体及其用途
WO2016054101A1 (en) 2014-09-29 2016-04-07 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
MX2018007089A (es) 2015-12-14 2019-01-30 Macrogenics Inc Moleculas biespecificas que tienen inmunorreactividad con pd-1 y ctla-4, y metodos de uso de las mismas.
BR112019012354A2 (pt) 2016-12-21 2019-11-26 Teneobio Inc anticorpos apenas de cadeia pesada anti-bcma
US11459394B2 (en) 2017-02-24 2022-10-04 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
IL312322A (en) 2017-06-20 2024-06-01 Teneobio Inc Anti-BCMA antibodies containing only heavy chains
MX2020003144A (es) * 2017-09-22 2020-07-28 Wuxi Biologics Ireland Ltd Nuevos complejos de polipeptidos biespecificos cd3/cd19.
CA3075693A1 (en) 2017-09-22 2019-03-28 WuXi Biologics Ireland Limited Bispecific polypeptide complexes
JP2020535181A (ja) * 2017-09-29 2020-12-03 ヤンセン バイオテツク，インコーポレーテツド 低用量抗体組成物を安定化する新規製剤
CN109706163A (zh) * 2017-10-26 2019-05-03 深圳新诺微环生物科技有限公司 微环dna表达连接人与动物靶细胞与效应细胞的桥接分子及其应用
MX2020008489A (es) 2018-02-15 2020-09-25 Macrogenics Inc Dominios de union a cd3 variantes y su uso en terapias de combinacion para el tratamiento de enfermedades.
WO2020018922A1 (en) * 2018-07-20 2020-01-23 Teneobio, Inc. Heavy chain antibodies binding to cd19
EP3891181A4 (en) * 2018-12-04 2022-08-17 Novartis AG BINDING MOLECULES AGAINST CD3 AND USES THEREOF
EP3953385A4 (en) * 2019-04-08 2022-12-21 Memorial Sloan Kettering Cancer Center CD19 ANTIBODIES AND METHODS OF USE THEREOF
JOP20210309A1 (ar) 2019-05-21 2023-01-30 Novartis Ag جزيئات ربط بـ cd19 واستخدامتها
US12435155B2 (en) 2020-02-21 2025-10-07 Macrogenics, Inc. CD137 binding molecules and uses thereof
HUE071594T2 (hu) 2021-01-28 2025-09-28 Regeneron Pharma Készítmények és módszerek a citokinfelszabadulási szindróma kezelésére
CN117940457A (zh) * 2021-09-13 2024-04-26 山东先声生物制药有限公司 抗人cd3抗体及其应用
KR20250004700A (ko) 2022-04-11 2025-01-08 리제너론 파마슈티칼스 인코포레이티드 보편적 종양 세포 사멸을 위한 조성물 및 방법
AU2024223918A1 (en) 2023-02-17 2025-09-11 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110206672A1 (en) * 2010-02-25 2011-08-25 Melvyn Little Antigen-Binding Molecule And Uses Thereof
CN102369021A (zh) * 2008-12-19 2012-03-07 宏观基因有限公司 共价双抗体及其用途
CN102725000A (zh) * 2010-01-19 2012-10-10 免疫医疗公司 靶向胰岛素-样生长因子i型受体(igf-1r)的新型单特异性和双特异性人源化抗体
US20140154253A1 (en) * 2012-07-13 2014-06-05 Zymeworks Inc. Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs
CN106414497A (zh) * 2014-05-29 2017-02-15 宏观基因有限公司 三特异性结合分子和其使用方法
CN106715470A (zh) * 2014-06-26 2017-05-24 宏观基因有限公司 与pd‑1和lag‑3具有免疫反应性的共价结合的双抗体和其使用方法

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE37983T1 (de) 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
WO1991003493A1 (en) 1989-08-29 1991-03-21 The University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
WO1991005548A1 (en) 1989-10-10 1991-05-02 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
JP2571874B2 (ja) 1989-11-06 1997-01-16 アルカーメス コントロールド セラピューティクス，インコーポレイテッド タンパク質マイクロスフェア組成物
JPH06507404A (ja) 1991-05-01 1994-08-25 ヘンリー　エム．ジャクソン　ファウンデイション　フォー　ザ　アドバンスメント　オブ　ミリタリー　メディスン 感染性の呼吸性疾患の治療方法
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
AU2605592A (en) 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
AU4755696A (en) 1995-01-05 1996-07-24 Board Of Regents Acting For And On Behalf Of The University Of Michigan, The Surface-modified nanoparticles and method of making and using same
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
CA2230494A1 (en) 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics Inc. Composition for sustained release of an agent
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
JP2000506165A (ja) 1996-03-04 2000-05-23 ザ ペン ステイト リサーチ ファウンデーション 細胞インターナリゼーションを増強するための物質および方法
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
WO1998031346A1 (en) 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
AU747231B2 (en) 1998-06-24 2002-05-09 Alkermes, Inc. Large porous particles emitted from an inhaler
EP1294904A1 (en) 2000-06-30 2003-03-26 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Heterodimeric fusion proteins
US6992234B2 (en) 2000-11-06 2006-01-31 The Jackson Laboratory FcRn-based therapeutics for the treatment of auto-immune disorders
ITRM20010408A1 (it) 2001-07-10 2003-01-10 Univ Napoli Federico Ii Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2.
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
ES2276735T3 (es) 2001-09-14 2007-07-01 Affimed Therapeutics Ag Anticuerpos fv multimericos de cadena sencilla en tandem.
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) * 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
ES2707152T3 (es) 2005-04-15 2019-04-02 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP5090366B2 (ja) 2005-12-16 2012-12-05 アイビーシー ファーマスーティカルズ，インク． 多価イムノグロブリン系生物活性アセンブリー
MX2008015524A (es) 2006-06-12 2009-01-13 Trubion Pharmaceuticals Inc Proteinas de union multivalentes monocatenarias con funcion efectora.
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
EP2059533B1 (en) 2006-08-30 2012-11-14 Genentech, Inc. Multispecific antibodies
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
LT2211904T (lt) * 2007-10-19 2016-11-25 Seattle Genetics, Inc. Cd19 surišantys agentai ir jų panaudojimas
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
WO2010028795A1 (en) 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Multivalent antibodies
WO2010028797A1 (en) 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Multivalent antibodies
WO2010028796A1 (en) 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Trispecific hexavalent antibodies
CA2755640C (en) 2009-03-20 2018-05-22 Genentech, Inc. Bispecific antibody with a single antigen-binding domain specific for both her3 and egfr
MX2011011925A (es) 2009-05-27 2011-12-06 Hoffmann La Roche Anticuerpos triespecificos o tetraespecificos.
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
CA2796633C (en) 2010-04-23 2020-10-27 Genentech, Inc. Production of heteromultimeric proteins
SG187682A1 (en) 2010-08-02 2013-03-28 Macrogenics Inc Covalent diabodies and uses thereof
WO2012156430A1 (en) 2011-05-17 2012-11-22 Trion Research Gmbh Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties
CA2836857C (en) 2011-05-21 2019-12-03 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
MX347818B (es) 2011-05-21 2017-05-15 Macrogenics Inc Dominios que enlazan suero desinmunizados y su uso para prolongar la vida media en suero.
WO2012162583A1 (en) 2011-05-26 2012-11-29 Ibc Pharmaceuticals, Inc. Design and construction of novel multivalent antibodies
US20150045540A1 (en) 2011-06-28 2015-02-12 Sea Lane Biotechnologies, Llc Multispecific stacked variable domain binding proteins
EP2729488A4 (en) 2011-07-06 2015-01-14 Medimmune Llc PROCESS FOR PREPARING MULTIMANT POLYPEPTIDES
KR102162413B1 (ko) * 2011-08-17 2020-10-07 글락소 그룹 리미티드 변형된 단백질 및 펩티드
CA2863944A1 (en) 2012-02-10 2013-08-15 Research Corporation Technologies, Inc. Fusion proteins comprising immunoglobulin constant domain-derived scaffolds
WO2013163427A1 (en) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
HK1203517A1 (en) 2012-05-24 2015-10-30 F. Hoffmann-La Roche Ag Multispecific antibodies
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JP2016510319A (ja) 2012-12-28 2016-04-07 アッヴィ・インコーポレイテッド 多価結合タンパク質組成物
CA3211863A1 (en) 2013-01-14 2014-07-17 Xencor, Inc. Novel heterodimeric proteins
EP2951203B1 (en) 2013-03-15 2019-05-22 Xencor, Inc. Heterodimeric proteins
US11384149B2 (en) * 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
UA116479C2 (uk) * 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2840091A1 (en) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
CN107484416A (zh) * 2014-09-26 2017-12-15 宏观基因有限公司 能够结合cd19和cd3的双特异性单价双抗体及其用途
WO2016054101A1 (en) * 2014-09-29 2016-04-07 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
RU2017129236A (ru) * 2015-01-26 2019-03-07 Макродженикс, Инк. Мультивалентные молекулы, содержащие dr5-связывающие домены
PE20181066A1 (es) * 2015-08-17 2018-07-04 Macrogenics Inc Diacuerpos monovalentes biespecificos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos
TW201720458A (zh) * 2015-12-04 2017-06-16 宏觀基因股份有限公司 能夠結合cd19 和cd3 的雙特異性單價雙抗體以及其用途
EP3448427A1 (en) * 2016-04-29 2019-03-06 CureVac AG Rna encoding an antibody
WO2017214096A1 (en) * 2016-06-07 2017-12-14 Macrogenics, Inc. Methods for the use of cd32b x cd79b-binding molecules in the treatment of inflammatory diseases and disorders
US11459394B2 (en) * 2017-02-24 2022-10-04 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
KR20200098590A (ko) * 2017-12-12 2020-08-20 마크로제닉스, 인크. 이중특이적 cd16-결합 분자 및 질환 치료에서의 그것의 용도
MX2020008489A (es) * 2018-02-15 2020-09-25 Macrogenics Inc Dominios de union a cd3 variantes y su uso en terapias de combinacion para el tratamiento de enfermedades.
CA3100398A1 (en) * 2018-05-18 2019-11-21 Macrogenics, Inc. Optimized gp41-binding molecules and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102369021A (zh) * 2008-12-19 2012-03-07 宏观基因有限公司 共价双抗体及其用途
CN102725000A (zh) * 2010-01-19 2012-10-10 免疫医疗公司 靶向胰岛素-样生长因子i型受体(igf-1r)的新型单特异性和双特异性人源化抗体
US20110206672A1 (en) * 2010-02-25 2011-08-25 Melvyn Little Antigen-Binding Molecule And Uses Thereof
US20140154253A1 (en) * 2012-07-13 2014-06-05 Zymeworks Inc. Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs
CN106414497A (zh) * 2014-05-29 2017-02-15 宏观基因有限公司 三特异性结合分子和其使用方法
CN106715470A (zh) * 2014-06-26 2017-05-24 宏观基因有限公司 与pd‑1和lag‑3具有免疫反应性的共价结合的双抗体和其使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
鲍静: "血小板特异性自身抗体和淋巴细胞亚群检测在免疫性血小板减少症中的临床价值", 《安徽医科大学学报》 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109957026A (zh) * 2017-12-22 2019-07-02 成都恩沐生物科技有限公司 共价多特异性抗体
CN111655733A (zh) * 2017-12-22 2020-09-11 成都恩沐生物科技有限公司 共价多特异性抗体
CN109402168A (zh) * 2018-10-30 2019-03-01 深圳新诺微环生物科技有限公司 微环dna表达连接her2阳性细胞与效应细胞的桥接分子及其应用
WO2020088605A1 (zh) * 2018-11-01 2020-05-07 安源医药科技（上海）有限公司 针对cd19和cd3的同源二聚体型双特异性抗体及其制备方法和用途
CN111138547A (zh) * 2018-11-01 2020-05-12 安源医药科技（上海）有限公司 针对cd19和cd3的同源二聚体型双特异性抗体及其制备方法和用途
CN112996807A (zh) * 2018-11-01 2021-06-18 安源医药科技（上海）有限公司 针对cd19和cd3的同源二聚体型双特异性抗体及其制备方法和用途
CN112111012A (zh) * 2019-06-20 2020-12-22 成都恩沐生物科技有限公司 共价多特异性抗体
CN112111012B (zh) * 2019-06-20 2023-07-04 成都恩沐生物科技有限公司 共价多特异性抗体
CN113488112A (zh) * 2021-06-10 2021-10-08 五邑大学 一种共价结合预测方法及装置

Also Published As

Publication number Publication date
US20200216537A1 (en) 2020-07-09
US20230399399A1 (en) 2023-12-14
CU20170041A7 (es) 2017-09-06
ES2935062T3 (es) 2023-03-01
PH12017500544A1 (en) 2017-08-07
AP2017009823A0 (en) 2017-03-31
NI201700037A (es) 2017-07-18
BR112017005988A2 (pt) 2017-12-19
MX375669B (es) 2025-03-06
CL2017000711A1 (es) 2017-12-15
MD20170040A2 (ro) 2017-07-31
UY36316A (es) 2016-04-29
US10633443B2 (en) 2020-04-28
TWI706960B (zh) 2020-10-11
EA201790719A1 (ru) 2017-07-31
JP6839075B2 (ja) 2021-03-03
AR101997A1 (es) 2017-01-25
EP3197917B1 (en) 2022-10-12
US20170247452A1 (en) 2017-08-31
US20250313628A1 (en) 2025-10-09
SG11201702310QA (en) 2017-04-27
MX2017003784A (es) 2017-06-28
EP3197917A4 (en) 2018-06-27
IL251377A0 (en) 2017-05-29
AU2015321546B2 (en) 2020-09-03
EP3197917A1 (en) 2017-08-02
CO2017002793A2 (es) 2017-06-20
KR20170063755A (ko) 2017-06-08
TW201617369A (zh) 2016-05-16
ZA201701985B (en) 2018-05-30
IL251377B (en) 2021-03-25
AU2015321546A1 (en) 2017-04-13
NZ730348A (en) 2024-03-22
CR20170109A (es) 2017-07-26
PE20170894A1 (es) 2017-07-12
DOP2017000083A (es) 2017-04-30
CA2962603A1 (en) 2016-03-31
MA40573A (fr) 2016-03-31
WO2016048938A1 (en) 2016-03-31
US11639386B2 (en) 2023-05-02
JP2017533891A (ja) 2017-11-16
TN2017000106A1 (en) 2018-07-04

Similar Documents

Publication Publication Date Title
AU2015321546B2 (en) Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof
TWI788327B (zh) 能夠結合cd137和腫瘤抗原的雙特異性結合分子及其用途
KR102294018B1 (ko) CD32B 및 CD79b에 결합할 수 있는 이중특이성 1가 Fc 디아바디 및 그것의 용도
US20190002563A1 (en) Bispecific Monovalent Diabodies That are Capable of Binding B7-H3 and CD3, and Uses Thereof
US20170157251A1 (en) Bi-Specific Monovalent Diabodies That are Capable of Binding CD19 and CD3, and Uses Thereof
CN107250161A (zh) 包含dr5‑结合结构域的多价分子
CN111971090A (zh) 双特异性egfr/cd16抗原结合蛋白
KR20190016079A (ko) 염증성 질환 및 장애의 치료에서 CD32B x CD79B-결합 분자의 사용 방법
CN111465618A (zh) 双特异性cd16-结合分子及其在疾病治疗中的用途
RU2805648C2 (ru) Биспецифические связывающие молекулы, способные связывать cd137 и опухолевые антигены, и варианты их применения
HK40113244A (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
EA040028B1 (ru) Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
HK1241895A1 (en) Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof
HK1241895B (en) Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof
BR112017005988B1 (pt) Diacorpo de fc monovalente biespecífico cd19 x cd3 capaz de realizar ligação específica a cd19 e a cd3, composição farmacêutica, complexo polipeptídico covalentemente associado, e polinucleotídeo

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20171215

WD01 Invention patent application deemed withdrawn after publication